SCHEMBL725075

SCHEMBL725075

OCCn1cc(-c2ccc(-c3cc4nccc(-c5cncs5)c4o3)cc2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 7/20 0.38
MAP4K4 O95819 1/20 0.38
FEN1 P39748 1/20 0.36
NAMPT P43490 1/20 0.35
IKBKE Q14164 2/20 0.35
TBK1 Q9UHD2 2/20 0.35
PDK2 Q15119 1/20 0.35
MAP4K1 Q92918 1/20 0.35
KIT P10721 1/20 0.34
PRKAB2 O43741 1/20 0.34
ABL1 P00519 1/20 0.34
CSF1R P07333 1/20 0.34
LYN P07948 1/20 0.34
PRKAG1 P54619 1/20 0.34
SIK1 P57059 1/20 0.34
PRKAA1 Q13131 1/20 0.34
SIK2 Q9H0K1 1/20 0.34
SIK3 Q9Y2K2 1/20 0.34
STING1 Q86WV6 1/20 0.33
PRMT5 O14744 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722231 0.85 MAP4K4 (0.42) METMAP4K4FEN1NAMPTIKBKE
SCHEMBL723453 0.85 CCNC (0.40) METCCNCCDK8
SCHEMBL724193 0.84 MET (0.46) METMAP4K4FEN1NAMPTIKBKE
SCHEMBL723361 0.84 MET (0.42) METMAP4K4FEN1NAMPTIKBKE
SCHEMBL724686 0.83 MET (0.42) METMAP4K4FEN1NAMPTIKBKE
SCHEMBL724853 0.81 CD38 (0.34)
SCHEMBL723996 0.80 MET (0.40) METMAP4K4NAMPTIKBKETBK1
SCHEMBL15209542 0.80 MET (0.40) METMAP4K4NAMPTIKBKETBK1
SCHEMBL723333 0.80 MET (0.40) METMAP4K4FEN1NAMPTIKBKE
SCHEMBL722187 0.80 CD38 (0.34) PRKAB2PRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB MET 1482/4885MAP4K4 1964/4885FEN1 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.